Drugs / Anti-CD70 CAR-T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06586658 | Sep 2024 → Jul 2027 expected | renal cell carcinoma | Shanghai Changzheng Hospital | Recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05990621 | Jul 2023 → Jan 2026 | malignant urinary system neoplasm | Changhai Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD70-CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06586658 ↗ |
| Modality | Cell therapy | “Anti-CD70 CAR-T cells are autologous genetically modified T cells.” NCT05990621 ↗ |
| Route | Intravenous | “cells will be infused intravenously” NCT05990621 ↗ |
| Target | CD70 | “Anti-CD70 CAR-T cells” NCT05990621 ↗ |